PolyPid (PYPD) EBITDA (2019 - 2026)
PolyPid (PYPD) posted EBITDA of $7.8 million for Q1 2026, down 9.03% sequentially from $8.5 million in Q4 2025, and up 2.39% YoY from $7.6 million in Q1 2025.
PolyPid (PYPD) EBITDA (2019 - 2026) Analysis & Trends
PolyPid has reported EBITDA for 8 years, with the latest figure at $7.8 million in Q1 2026.
- Quarterly EBITDA rose 2.39% year-over-year to $7.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.1 million (up 13.11% YoY) and the FY2025 annual result came in at -$33.0 million, down 17.62% from the prior year.
- EBITDA declined to $7.8 million in Q1 2026 per PYPD's latest filing, from $8.5 million in the prior quarter.
- Over five years, EBITDA peaked at $12.0 million in Q1 2022 and troughed at $5.3 million in Q3 2023.
- A 5-year average of $7.7 million and a median of $7.5 million in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2025: EBITDA plunged 51.57% in 2022, then soared 53.62% in 2025.
- Over 5 years, EBITDA stood at $6.6 million in 2022, then slipped by 9.27% to $6.0 million in 2023, then surged by 37.04% to $8.2 million in 2024, then increased by 3.76% to $8.5 million in 2025, then declined by 9.03% to $7.8 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered $7.8 million, $8.5 million, and $7.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | PolyPid | 113.30 Mn | 106.53 Mn | - | 7.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.37 Mn |
| Mar 31, 2026 | 7.76 Mn |
| Dec 31, 2025 | 8.53 Mn |
| Sep 30, 2025 | 7.46 Mn |
| Jun 30, 2025 | 9.40 Mn |
| Mar 31, 2025 | 7.58 Mn |
| Dec 31, 2024 | 8.22 Mn |
| Sep 30, 2024 | 7.39 Mn |
| Jun 30, 2024 | 6.12 Mn |
| Mar 31, 2024 | 6.30 Mn |
| Dec 31, 2023 | 6.00 Mn |
| Sep 30, 2023 | 5.26 Mn |
| Jun 30, 2023 | 5.82 Mn |
| Mar 31, 2023 | 5.79 Mn |
| Dec 31, 2022 | 6.61 Mn |
| Sep 30, 2022 | 8.76 Mn |
| Jun 30, 2022 | 11.56 Mn |
| Mar 31, 2022 | 11.95 Mn |
| Dec 31, 2021 | 13.65 Mn |
| Sep 30, 2021 | 10.06 Mn |